LON:PXS Provexis (PXS) Share Price, News & Analysis GBX 1.10 +0.05 (+4.76%) As of 05/29/2026 12:13 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Provexis Stock (LON:PXS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Provexis alerts:Sign Up Key Stats Today's Range 1▼ 1.1050-Day Range 0.90▼ 1.2552-Week Range 0.46▼ 1.55Volume311,637 shsAverage Volume2.70 million shsMarket Capitalization£25.80 millionP/E RatioN/ADividend Yield5.06%Price TargetN/AConsensus RatingN/A Company Overview Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company's syrup and powder versions of Fruitflow are used in various foods, beverages, and dietary supplement formats. It offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and heart function. The company sells its products through distributors and online channels. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom. Read More Receive PXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provexis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXS Stock News HeadlinesProvexis Secures Shareholder Support and Advances in Chinese MarketNovember 21, 2025 | tipranks.comAIM Market Roundup: Provexis, Geo Exploration, SabienNovember 19, 2025 | sg.finance.yahoo.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.May 30 at 1:00 AM | Porter & Company (Ad)Provexis Faces Temporary Trading Suspension Amid Financial Reporting DelaySeptember 30, 2025 | tipranks.comPhase I trial finds topical PXS-6302 generally well tolerated in established skin scarsSeptember 12, 2025 | msn.comProvexis (LON:PXS) Is In A Strong Position To Grow Its BusinessJune 28, 2025 | finance.yahoo.comParagon Care Limited (PXS) Receives a Buy from Ord MinnettFebruary 28, 2025 | markets.businessinsider.comProvexis Grants Options and Warrants to CEO and ConsultantsJanuary 7, 2025 | tipranks.comSee More Headlines PXS Stock Analysis - Frequently Asked Questions How have PXS shares performed this year? Provexis' stock was trading at GBX 0.90 on January 1st, 2026. Since then, PXS stock has increased by 22.2% and is now trading at GBX 1.10. How were Provexis' earnings last quarter? Provexis plc (LON:PXS) released its earnings results on Wednesday, December, 31st. The company reported ($0.01) earnings per share (EPS) for the quarter. Provexis had a negative net margin of 69.30% and a negative trailing twelve-month return on equity of 49.45%. How do I buy shares of Provexis? Shares of PXS stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Provexis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provexis investors own include Reckitt Benckiser Group (RB), Taylor Wimpey (TW), Bionano Genomics (BNGO), Bristol Myers Squibb (BMY), Bumble (BMBL), BEST (BEST) and Alibaba Group (BABA). Company Calendar Last Earnings12/31/2025Today5/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryTransportation Current SymbolLON:PXS CIKN/A Webwww.provexis.org Phone+44-1753-861777FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£619.15 thousand Net Margins-69.30% Pretax MarginN/A Return on Equity-49.45% Return on Assets-56.14% Debt Debt-to-Equity RatioN/A Current Ratio3.65 Quick Ratio6.21 Sales & Book Value Annual Sales£871.27 thousand Price / Sales29.62 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 0.01 per share Price / Book128.24Miscellaneous Outstanding Shares2,345,891,000Free FloatN/AMarket Cap£25.80 million OptionableNot Optionable Beta0.66 Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (LON:PXS) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersMassive Data Leak Exposes 512,000-Line Code That Could Change Society Forever"You won't believe what I discovered at 4 World Trade Center" When our financial media correspondent travel...Chaikin Analytics | SponsoredI paid $5,000 to hear Elon say thisOne investor paid $5,000 to be in a private room with Elon Musk in Los Angeles - and what he heard confirmed a...InvestorPlace | SponsoredOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including powe...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredMusk lights fire under Swiss chipmaker?While investors chase the SpaceX IPO, one little-known Swiss chipmaker - 148 times smaller than NVIDIA - has q...Brownstone Research | SponsoredTrump’s real warA 29-page National Security Strategy document - what analyst Porter Stansberry calls the 'Donroe Doctrine' - c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provexis plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Provexis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
